NAD+ vs Rapamycin
A side-by-side research comparison of NAD+ and Rapamycin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NAD+ | Rapamycin |
|---|---|---|
| Full name | Nicotinamide Adenine Dinucleotide (NAD+ / NMN / NR) | Rapamycin (Sirolimus) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved (off-label for longevity) |
| Mechanism | NAD+ serves as cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Declining NAD+ impairs mitochondrial function and epigenetic maintenance. Restoration reactivates longevity pathways. | Inhibits mTOR complex 1 (mTORC1), reducing cellular growth signaling and activating autophagy - the cellular recycling process. Mimics caloric restriction at the molecular level. |
| Molecular weight | 663.4 Da | 914.17 Da |
| Half-life | 1-4 hours (IV), 4-8h (oral precursors) | ~62 hours |
| Bioavailability | 100% (IV), variable (oral 5-30%) | ~14% oral |
| Typical dose | 250-500mg IV or 500-1000mg NMN oral | 3-6 mg |
| Frequency | Weekly (IV) or Daily (oral) | Once weekly |
| Route | IV infusion or Oral (precursors) | Oral tablet |
NAD+ reported benefits
- Restored cellular energy
- Enhanced DNA repair
- Sirtuin activation
- Improved mitochondrial function
- Cognitive clarity
- Anti-aging
Rapamycin reported benefits
- Enhanced autophagy
- Immune rejuvenation
- Anti-aging cellular effects
- Cancer risk reduction
- Improved vaccine response (elderly)
- Longevity extension
Related comparisons
Research and educational reference only. Not medical advice.